travoprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 2716 157283-68-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • izba
  • travoprost
  • travaprost
  • travatan
  • travatanz
A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
  • Molecular weight: 500.56
  • Formula: C26H35F3O6
  • CLOGP: 3.92
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 3
  • TPSA: 96.22
  • ALOGS: -4.82
  • ROTB: 14
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1,ZAP70 25
kinase-selectivity-class AXL,GRK2,MAP2K6 3
pfas-class PFAS structural alert (1 = True, 0 = False) 1

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 2001 EMA
March 16, 2001 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 462.39 20.05 294 7111 303634 90317408
Intraocular pressure increased 360.15 20.05 89 7316 7004 90614038
Ocular hyperaemia 291.48 20.05 108 7297 33690 90587352
Eye irritation 269.04 20.05 102 7303 33876 90587166
Malignant mediastinal neoplasm 211.96 20.05 43 7362 1365 90619677
Glaucoma 192.43 20.05 70 7335 20685 90600357
Blood immunoglobulin E increased 172.58 20.05 45 7360 4380 90616662
Eye pain 168.79 20.05 79 7326 44089 90576953
Product delivery mechanism issue 115.74 20.05 22 7383 494 90620548
Product packaging quantity issue 106.48 20.05 25 7380 1577 90619465
Bronchiectasis 94.81 20.05 43 7362 22287 90598755
Full blood count abnormal 93.97 20.05 50 7355 36547 90584495
Eye pruritus 72.66 20.05 39 7366 28988 90592054
Product container issue 69.92 20.05 19 7386 2162 90618880
Visual acuity reduced 65.83 20.05 34 7371 23376 90597666
Vision blurred 62.94 20.05 60 7345 110233 90510809
Nasal congestion 58.59 20.05 51 7354 83363 90537679
Foreign body sensation in eyes 57.91 20.05 18 7387 3282 90617760
Dry eye 56.72 20.05 43 7362 57888 90563154
Rhinorrhoea 54.13 20.05 50 7355 88266 90532776
Intraocular pressure decreased 52.19 20.05 9 7396 114 90620928
Eye allergy 49.46 20.05 13 7392 1302 90619740
Medical device removal 49.29 20.05 13 7392 1320 90619722
Eye disorder 47.58 20.05 29 7376 27361 90593681
Eye inflammation 42.68 20.05 18 7387 7833 90613209
Cough 42.18 20.05 93 7312 368869 90252173
Conjunctival hyperaemia 42.14 20.05 14 7391 3155 90617887
Product container seal issue 41.37 20.05 8 7397 197 90620845
Growth of eyelashes 40.32 20.05 8 7397 226 90620816
Normal tension glaucoma 38.66 20.05 6 7399 37 90621005
Retinal disorder 35.92 20.05 11 7394 1908 90619134
Product quality issue 35.76 20.05 38 7367 79287 90541755
Photophobia 35.61 20.05 22 7383 21247 90599795
Expired product administered 34.75 20.05 15 7390 6907 90614135
Intraocular pressure test abnormal 34.52 20.05 7 7398 221 90620821
Visual impairment 34.44 20.05 48 7357 132317 90488725
Reaction to preservatives 34.20 20.05 7 7398 232 90620810
Liquid product physical issue 33.82 20.05 10 7395 1540 90619502
Lacrimation increased 33.11 20.05 23 7382 27039 90594003
Eye swelling 31.40 20.05 23 7382 29363 90591679
Blindness 31.15 20.05 22 7383 26546 90594496
Corneal disorder 31.11 20.05 10 7395 2032 90619010
Hypoacusis 30.22 20.05 22 7383 27828 90593214
Asthma 29.88 20.05 63 7342 242097 90378945
Corneal opacity 29.50 20.05 8 7397 903 90620139
Subacute cutaneous lupus erythematosus 29.19 20.05 11 7394 3571 90617471
Accidental exposure to product 27.92 20.05 25 7380 42341 90578701
Dark circles under eyes 27.51 20.05 7 7398 617 90620425
Optic nerve injury 27.31 20.05 7 7398 635 90620407
Ocular discomfort 26.18 20.05 12 7393 6358 90614684
Corneal irritation 25.24 20.05 3 7402 0 90621042
Blepharitis 24.60 20.05 10 7395 3966 90617076
Eyelid irritation 24.18 20.05 7 7398 1001 90620041
Gastrointestinal bacterial infection 23.71 20.05 7 7398 1073 90619969
Ulcerative keratitis 22.45 20.05 9 7396 3444 90617598
Product use complaint 22.25 20.05 9 7396 3524 90617518
Visual field defect 21.86 20.05 11 7394 7155 90613887
Blepharal pigmentation 21.58 20.05 4 7401 78 90620964
Punctate keratitis 21.22 20.05 6 7399 790 90620252
Gastroenteritis salmonella 20.83 20.05 6 7399 844 90620198
Eye discharge 20.39 20.05 11 7394 8247 90612795
Eyelid margin crusting 20.30 20.05 7 7398 1765 90619277
Product administration error 20.26 20.05 17 7388 26406 90594636

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 497.54 18.93 200 4192 62424 42554519
Eye irritation 177.99 18.93 60 4332 11258 42605685
Intraocular pressure increased 167.10 18.93 50 4342 6383 42610560
Ocular hyperaemia 140 18.93 55 4337 15908 42601035
Product delivery mechanism issue 92.37 18.93 17 4375 249 42616694
Eye pain 83.86 18.93 39 4353 16991 42599952
Growth of eyelashes 66.29 18.93 11 4381 84 42616859
Visual acuity reduced 45.18 18.93 26 4366 17524 42599419
Eye pruritus 43.66 18.93 22 4370 11390 42605553
Expired product administered 42.36 18.93 16 4376 4147 42612796
Medical device removal 41.21 18.93 8 4384 158 42616785
Adrenal cyst 39.88 18.93 8 4384 188 42616755
Eye inflammation 35.04 18.93 13 4379 3205 42613738
Hypotony of eye 32.02 18.93 7 4385 252 42616691
Corneal oedema 31.55 18.93 10 4382 1538 42615405
Bursitis infective 30.12 18.93 8 4384 660 42616283
Visual impairment 29.92 18.93 29 4363 43084 42573859
Product quality issue 29.57 18.93 20 4372 17862 42599081
Blepharitis 29.37 18.93 10 4382 1923 42615020
Tongue haemorrhage 29.19 18.93 8 4384 743 42616200
Glaucoma 28.93 18.93 15 4377 8233 42608710
Product container issue 27.64 18.93 8 4384 906 42616037
Foreign body sensation in eyes 27.29 18.93 8 4384 947 42615996
Blindness 27.12 18.93 19 4373 17959 42598984
Cystoid macular oedema 26.67 18.93 8 4384 1025 42615918
Vision blurred 26.31 18.93 30 4362 53669 42563274
Blood potassium abnormal 26.20 18.93 9 4383 1777 42615166
Conjunctival scar 25.53 18.93 6 4386 300 42616643
Blindness unilateral 25.45 18.93 12 4380 5376 42611567
Vertebral end plate inflammation 22.10 18.93 5 4387 211 42616732
Vitreous floaters 21.78 18.93 10 4382 4220 42612723
Eyelid margin crusting 21.32 18.93 6 4386 614 42616329
Platelet disorder 20.83 18.93 8 4384 2166 42614777
Electrolyte depletion 20.72 18.93 5 4387 280 42616663
Product packaging quantity issue 20.56 18.93 7 4385 1346 42615597
Retinal detachment 20.43 18.93 11 4381 6514 42610429
Hepatitis fulminant 20.26 18.93 10 4382 4949 42611994
Tension 19.86 18.93 8 4384 2456 42614487
Intraocular pressure test abnormal 19.23 18.93 4 4388 113 42616830
Eye disorder 19.22 18.93 13 4379 11599 42605344

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant mediastinal neoplasm 209.70 17.55 42 8415 1336 110579506
Intraocular pressure increased 206.36 17.55 62 8395 10814 110570028
Ocular hyperaemia 160.00 17.55 72 8385 39214 110541628
Blood immunoglobulin E increased 147.76 17.55 44 8413 7438 110573404
Eye irritation 141.62 17.55 63 8394 33389 110547453
Eye pain 92.85 17.55 54 8403 50045 110530797
Visual acuity reduced 79.72 17.55 42 8415 32131 110548711
Full blood count abnormal 74.79 17.55 49 8408 56003 110524839
Bronchiectasis 74.76 17.55 42 8415 36451 110544391
Medical device removal 67.59 17.55 15 8442 786 110580056
Rhinorrhoea 65.99 17.55 58 8399 102608 110478234
Glaucoma 60.38 17.55 31 8426 22486 110558356
Nasal congestion 54.28 17.55 51 8406 98231 110482611
Conjunctival hyperaemia 52.76 17.55 19 8438 5812 110575030
Blepharitis 49.47 17.55 17 8440 4535 110576307
Corneal oedema 43.03 17.55 14 8443 3159 110577683
Vision blurred 42.74 17.55 51 8406 128971 110451871
Eye inflammation 41.13 17.55 18 8439 9153 110571689
Adrenal cyst 39.91 17.55 8 8449 255 110580587
Normal tension glaucoma 36.58 17.55 6 8451 59 110580783
Corneal disorder 33.36 17.55 11 8446 2586 110578256
Erythema of eyelid 32.60 17.55 12 8445 3903 110576939
Cough 32.58 17.55 93 8364 461548 110119294
Cystoid macular oedema 32.55 17.55 11 8446 2789 110578053
Intraocular pressure decreased 30.13 17.55 6 8451 185 110580657
Growth of eyelashes 29.94 17.55 6 8451 191 110580651
Hypotony of eye 29.87 17.55 7 8450 468 110580374
Hepatitis fulminant 29.54 17.55 14 8443 8546 110572296
Asthma 28.95 17.55 61 8396 250230 110330612
Keratic precipitates 28.77 17.55 7 8450 549 110580293
Tongue haemorrhage 27.81 17.55 8 8449 1197 110579645
Corneal opacity 27.51 17.55 8 8449 1243 110579599
Visual field defect 27.38 17.55 14 8443 10058 110570784
Conjunctival scar 26.47 17.55 6 8451 346 110580496
Subacute cutaneous lupus erythematosus 26.35 17.55 11 8446 4983 110575859
Retinal disorder 26.33 17.55 9 8448 2361 110578481
Eye disorder 26.28 17.55 20 8437 28886 110551956
Bursitis infective 26.20 17.55 8 8449 1468 110579374
Eye pruritus 26.17 17.55 21 8436 32754 110548088
Vitreous floaters 25.72 17.55 13 8444 9121 110571721
Choroidal effusion 25.50 17.55 7 8450 883 110579959
Corneal irritation 25.44 17.55 3 8454 0 110580842
Blood potassium abnormal 25.17 17.55 10 8447 3995 110576847
Blindness 24.26 17.55 21 8436 36338 110544504
Vertebral end plate inflammation 23.58 17.55 5 8452 211 110580631
Punctate keratitis 23.41 17.55 7 8450 1197 110579645
Foreign body sensation in eyes 23.33 17.55 9 8448 3325 110577517
Tension 22.88 17.55 10 8447 5068 110575774
Trabeculectomy 22.71 17.55 4 8453 62 110580780
Blindness transient 21.35 17.55 10 8447 5946 110574896
Lacrimation increased 20.90 17.55 18 8439 30932 110549910
Ulcerative keratitis 20.23 17.55 9 8448 4757 110576085
Photophobia 19.49 17.55 16 8441 25755 110555087
Hypoglycaemia 19.24 17.55 33 8424 116071 110464771
Electrolyte depletion 19.21 17.55 5 8452 515 110580327
Platelet disorder 19.07 17.55 8 8449 3667 110577175
Stag horn calculus 18.73 17.55 4 8453 175 110580667
Open angle glaucoma 18.72 17.55 5 8452 569 110580273
Dengue fever 18.53 17.55 6 8451 1333 110579509
Eye discharge 17.71 17.55 10 8447 8744 110572098
Tracheo-oesophageal fistula 17.68 17.55 5 8452 704 110580138

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01EE04 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Prostaglandin analogues
FDA CS M0017805 Prostaglandins
FDA EPC N0000175454 Prostaglandin Analog
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:66900 prostaglandin receptor agonist
CHEBI has role CHEBI:66981 ophthalmology drug

Related Drugs by ATC class:

S01EE Prostaglandin analogues 6 drugs
bimatoprostdorzolamidelatanoprostlatanoprostene bunodnetarsudiltafluprost

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Open-angle glaucoma indication 84494001 DOID:1067
Iritis contraindication 65074000 DOID:1406
Uveitis contraindication 128473001 DOID:13141
Cystoid macular edema contraindication 193387007 DOID:4447




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
75MCG IDOSE TR GLAUKOS N218010 Dec. 13, 2023 RX IMPLANT INTRACAMERAL 12201557 June 18, 2030 METHOD OF LOWERING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
75MCG IDOSE TR GLAUKOS N218010 Dec. 13, 2023 RX IMPLANT INTRACAMERAL Dec. 13, 2026 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin F2-alpha receptor GPCR AGONIST Ki 7.28 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Prostaglandin E2 receptor EP3 subtype GPCR Ki 5.46 SCIENTIFIC LITERATURE

External reference:

IDSource
4021261 VUID
N0000148702 NUI
D01964 KEGG_DRUG
4021261 VANDF
C0937916 UMLSCUI
CHEBI:746859 CHEBI
CHEMBL1200799 ChEMBL_ID
D000069557 MESH_DESCRIPTOR_UI
DB00287 DRUGBANK_ID
7102 IUPHAR_LIGAND_ID
7775 INN_ID
WJ68R08KX9 UNII
5282226 PUBCHEM_CID
1539201 RXNORM
15936 MMSL
200905 MMSL
41255 MMSL
88661 MMSL
d04753 MMSL
009114 NDDF
129493000 SNOMEDCT_US
391664000 SNOMEDCT_US
WJ68R08KX9 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Travatan Z HUMAN PRESCRIPTION DRUG LABEL 1 0078-0946 SOLUTION/ DROPS 0.04 mg OPHTHALMIC NDA 25 sections
Travatan Z HUMAN PRESCRIPTION DRUG LABEL 1 0078-0946 SOLUTION/ DROPS 0.04 mg OPHTHALMIC NDA 25 sections
Travoprost Ophthalmic Solution, 0.004% HUMAN PRESCRIPTION DRUG LABEL 1 0378-9651 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 23 sections
Travoprost Ophthalmic Solution HUMAN PRESCRIPTION DRUG LABEL 1 0781-6185 SOLUTION/ DROPS 0.04 mg OPHTHALMIC NDA authorized generic 22 sections
Travoprost Ophthalmic Soluton HUMAN PRESCRIPTION DRUG LABEL 1 25021-002 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 26 sections
iDose TR HUMAN PRESCRIPTION DRUG LABEL 1 25357-100 IMPLANT 75 ug INTRACAMERAL NDA 23 sections
Travoprost Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 42571-130 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 42571-130 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost ophthalmic solution Human Prescription Drug Label 1 46708-625 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost HUMAN PRESCRIPTION DRUG LABEL 1 51407-731 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travatan Z HUMAN PRESCRIPTION DRUG LABEL 1 54868-5968 SOLUTION 0.04 mg OPHTHALMIC NDA 22 sections
Travoprost HUMAN PRESCRIPTION DRUG LABEL 1 60505-0593 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic Solution USP, 0.004%Travoprost Human Prescription Drug Label 1 62332-510 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost ophthalmic solution Human Prescription Drug Label 1 62332-625 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections
Travatan Z HUMAN PRESCRIPTION DRUG LABEL 1 66758-095 SOLUTION/ DROPS 0.04 mg OPHTHALMIC NDA 23 sections
Travoprost Ophthalmic Solution Human Prescription Drug Label 1 68083-601 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic Solution Human Prescription Drug Label 1 68083-602 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic Solution HUMAN PRESCRIPTION DRUG LABEL 1 68462-943 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost HUMAN PRESCRIPTION DRUG LABEL 1 70069-586 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 17 sections
Travoprost HUMAN PRESCRIPTION DRUG LABEL 1 70069-587 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 17 sections
Travoprost Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 71335-2738 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 71335-2888 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 72162-2432 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections